IS8426A - Bísýklísk pýrasólýl og imídasólýl efnasambönd og notkun þeirra - Google Patents
Bísýklísk pýrasólýl og imídasólýl efnasambönd og notkun þeirraInfo
- Publication number
- IS8426A IS8426A IS8426A IS8426A IS8426A IS 8426 A IS8426 A IS 8426A IS 8426 A IS8426 A IS 8426A IS 8426 A IS8426 A IS 8426A IS 8426 A IS8426 A IS 8426A
- Authority
- IS
- Iceland
- Prior art keywords
- imidazolyl compounds
- bicyclic pyrazolyl
- pyrazolyl
- bicyclic
- imidazolyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51828003P | 2003-11-07 | 2003-11-07 | |
PCT/IB2004/003522 WO2005044822A1 (en) | 2003-11-07 | 2004-10-25 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IS8426A true IS8426A (is) | 2006-04-21 |
Family
ID=34572986
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS8426A IS8426A (is) | 2003-11-07 | 2006-04-21 | Bísýklísk pýrasólýl og imídasólýl efnasambönd og notkun þeirra |
Country Status (29)
Country | Link |
---|---|
US (2) | US7151097B2 (is) |
EP (1) | EP1682554A1 (is) |
JP (2) | JP4056549B2 (is) |
KR (1) | KR20060086396A (is) |
CN (1) | CN1886407A (is) |
AP (1) | AP2006003601A0 (is) |
AR (1) | AR046831A1 (is) |
AU (1) | AU2004286909A1 (is) |
BR (1) | BRPI0416299A (is) |
CA (1) | CA2544752A1 (is) |
CR (1) | CR8387A (is) |
DO (1) | DOP2004001024A (is) |
EA (1) | EA009742B1 (is) |
EC (1) | ECSP066549A (is) |
GT (1) | GT200400226A (is) |
HR (1) | HRP20060166A2 (is) |
IL (1) | IL175283A0 (is) |
IS (1) | IS8426A (is) |
MA (1) | MA28151A1 (is) |
MX (1) | MXPA06005023A (is) |
NL (1) | NL1027434C2 (is) |
NO (1) | NO20062618L (is) |
OA (1) | OA13280A (is) |
PA (1) | PA8616801A1 (is) |
PE (1) | PE20050576A1 (is) |
TN (1) | TNSN06129A1 (is) |
TW (2) | TWI280245B (is) |
WO (1) | WO2005044822A1 (is) |
ZA (1) | ZA200603594B (is) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10138275A1 (de) * | 2001-08-10 | 2003-02-27 | Boehringer Ingelheim Pharma | Verbindungen zur Beseitigung der Anhedonie |
EP1603585A2 (en) * | 2003-03-14 | 2005-12-14 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74 |
US7151097B2 (en) * | 2003-11-07 | 2006-12-19 | Pfizer Inc. | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof |
ITMI20041032A1 (it) * | 2004-05-24 | 2004-08-24 | Neuroscienze S C A R L | Compositi farmaceutici |
US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
US20060025448A1 (en) | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
WO2006035310A2 (en) * | 2004-09-27 | 2006-04-06 | Pfizer Products Inc. | Process for preparing bicyclic pyrazolyl compounds |
PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
CA2605479A1 (en) * | 2005-04-20 | 2006-10-26 | Pfizer Products Inc. | Acylaminobicyclic heteroaromatic compounds and uses thereof |
CA2609783A1 (en) * | 2005-05-27 | 2006-12-07 | Pfizer Products Inc. | Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss |
US8378117B2 (en) * | 2005-09-23 | 2013-02-19 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
US7825151B2 (en) * | 2005-09-23 | 2010-11-02 | Janssen Pharmaceutica Nv | Hexahydro-cyclooctyl pyrazole cannabinoid modulators |
US8378096B2 (en) * | 2005-09-23 | 2013-02-19 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
EP1951678A1 (en) * | 2005-10-21 | 2008-08-06 | Mitsubishi Tanabe Pharma Corporation | Pyrazole compounds having cannabinoid receptor (cb1) antagonizing activity |
WO2007060525A2 (en) | 2005-11-28 | 2007-05-31 | Pfizer Products Inc. | Process for preparing bicyclic pyrazolyl and imidazolyl compounds |
MX2008010899A (es) * | 2006-02-23 | 2008-11-27 | Pfizer Ltd | Piperidinoilpirrolidinas agonistas del receptor de melanocortina tipo 4. |
EP2742936A1 (en) | 2006-05-16 | 2014-06-18 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound and use thereof |
WO2008048648A2 (en) * | 2006-10-17 | 2008-04-24 | Acadia Pharmaceuticals Inc. | Cb1-modulating compounds and their use |
KR20090064478A (ko) | 2006-11-13 | 2009-06-18 | 화이자 프로덕츠 인크. | 디아릴, 디피리디닐 및 아릴-피리디닐 유도체, 및 이들의 용도 |
WO2009032754A2 (en) * | 2007-08-31 | 2009-03-12 | Kalypsys, Inc. | Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease |
JP2010043063A (ja) | 2008-05-09 | 2010-02-25 | Agency For Science Technology & Research | 川崎病の診断及び治療 |
WO2010015972A1 (en) * | 2008-08-06 | 2010-02-11 | Pfizer Limited | Diazepine and diazocane compounds as mc4 agonists |
US9549006B2 (en) * | 2013-07-31 | 2017-01-17 | Cisco Technology, Inc. | Self-adaptive sample period for content sharing in communication sessions |
EA033667B1 (ru) * | 2013-11-08 | 2019-11-14 | Incyte Holdings Corp | Способ синтеза ингибитора индоламин-2,3-диоксигеназы |
US11504416B2 (en) | 2018-09-04 | 2022-11-22 | Paw Power, Inc. | Formulation with cannabinoids |
US11191814B2 (en) | 2018-09-04 | 2021-12-07 | Paw Power, Inc. | Pet food formulation with cannabinoids |
MX2022000314A (es) * | 2019-08-09 | 2022-02-10 | Nihon Nohyaku Co Ltd | Derivado de oxazepinona, insecticida agricola/horticola que contiene el mismo, y metodo para usar el mismo. |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001234958A1 (en) | 2000-02-11 | 2001-08-20 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
JP2005507875A (ja) | 2001-08-31 | 2005-03-24 | ユニバーシティ オブ コネチカット | カンナビノイド受容体に作用する新規なピラゾール類似体 |
DE60207744T2 (de) | 2001-09-24 | 2006-08-03 | Bayer Pharmaceuticals Corp., West Haven | Verfahren zur herstellung von 1,5,6,7-tetrahydropyrrolo[3,2-c]derivaten zur behandlung der fettleibigkeit |
GB0207249D0 (en) | 2002-03-27 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
CA2502511A1 (en) * | 2002-10-18 | 2004-05-29 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
US7129239B2 (en) * | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) * | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US7329658B2 (en) * | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7176210B2 (en) * | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) * | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US20040214856A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7268133B2 (en) * | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7423031B2 (en) | 2003-05-01 | 2008-09-09 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
WO2004099157A1 (en) * | 2003-05-07 | 2004-11-18 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US20040259887A1 (en) | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US20050026983A1 (en) | 2003-07-30 | 2005-02-03 | Pfizer Inc | Imidazole compounds and uses thereof |
US7151097B2 (en) * | 2003-11-07 | 2006-12-19 | Pfizer Inc. | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof |
WO2006035310A2 (en) * | 2004-09-27 | 2006-04-06 | Pfizer Products Inc. | Process for preparing bicyclic pyrazolyl compounds |
-
2004
- 2004-10-22 US US10/971,599 patent/US7151097B2/en not_active Expired - Fee Related
- 2004-10-25 OA OA1200600145A patent/OA13280A/en unknown
- 2004-10-25 EA EA200600647A patent/EA009742B1/ru not_active IP Right Cessation
- 2004-10-25 CN CNA2004800352698A patent/CN1886407A/zh active Pending
- 2004-10-25 KR KR1020067008880A patent/KR20060086396A/ko active IP Right Grant
- 2004-10-25 JP JP2006538974A patent/JP4056549B2/ja not_active Expired - Fee Related
- 2004-10-25 AU AU2004286909A patent/AU2004286909A1/en not_active Abandoned
- 2004-10-25 AP AP2006003601A patent/AP2006003601A0/xx unknown
- 2004-10-25 MX MXPA06005023A patent/MXPA06005023A/es not_active Application Discontinuation
- 2004-10-25 EP EP04769741A patent/EP1682554A1/en not_active Withdrawn
- 2004-10-25 WO PCT/IB2004/003522 patent/WO2005044822A1/en active Application Filing
- 2004-10-25 BR BRPI0416299-4A patent/BRPI0416299A/pt not_active IP Right Cessation
- 2004-10-25 CA CA002544752A patent/CA2544752A1/en not_active Abandoned
- 2004-11-02 PA PA20048616801A patent/PA8616801A1/es unknown
- 2004-11-02 TW TW093133372A patent/TWI280245B/zh not_active IP Right Cessation
- 2004-11-02 TW TW095142275A patent/TW200716135A/zh unknown
- 2004-11-03 DO DO2004001024A patent/DOP2004001024A/es unknown
- 2004-11-04 PE PE2004001074A patent/PE20050576A1/es not_active Application Discontinuation
- 2004-11-04 GT GT200400226A patent/GT200400226A/es unknown
- 2004-11-05 NL NL1027434A patent/NL1027434C2/nl not_active IP Right Cessation
- 2004-11-05 AR ARP040104075A patent/AR046831A1/es not_active Application Discontinuation
-
2006
- 2006-04-21 IS IS8426A patent/IS8426A/is unknown
- 2006-04-27 IL IL175283A patent/IL175283A0/en unknown
- 2006-05-04 HR HR20060166A patent/HRP20060166A2/xx not_active Application Discontinuation
- 2006-05-05 CR CR8387A patent/CR8387A/es not_active Application Discontinuation
- 2006-05-05 MA MA29005A patent/MA28151A1/fr unknown
- 2006-05-05 TN TNP2006000129A patent/TNSN06129A1/fr unknown
- 2006-05-05 ZA ZA200603594A patent/ZA200603594B/en unknown
- 2006-05-05 EC EC2006006549A patent/ECSP066549A/es unknown
- 2006-06-07 NO NO20062618A patent/NO20062618L/no not_active Application Discontinuation
- 2006-09-07 US US11/470,695 patent/US20070027133A1/en not_active Abandoned
-
2007
- 2007-07-12 JP JP2007183117A patent/JP2007302685A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS8426A (is) | Bísýklísk pýrasólýl og imídasólýl efnasambönd og notkun þeirra | |
DE502004011106D1 (de) | 6-arylmethyl-substituierte pyrazolopyrimidine | |
ATE512148T1 (de) | Pyrazolo- und imidazopyrimidinderivate | |
ATE365161T1 (de) | Pyrazolverbindungen | |
DK1648899T3 (da) | Imidazopyrimidiner og triazolopyrimidiner: benzodiazepinreceptorligander | |
IL175151A0 (en) | Bicyclic pyrazolone cytokine inhibitors | |
GB0300804D0 (en) | Compounds and their use | |
GB0301143D0 (en) | Compounds and their use | |
GB0317133D0 (en) | Compounds and their use | |
GB0309319D0 (en) | Compounds and their use | |
GB0301147D0 (en) | Compounds and their use | |
GB0320064D0 (en) | Compounds and their use | |
GB0320062D0 (en) | Compounds and their use | |
GB0317283D0 (en) | Compounds and their use | |
GB0317281D0 (en) | Compounds and their use | |
GB0317279D0 (en) | Compounds and their use | |
GB0317278D0 (en) | Compounds and their use | |
GB0316205D0 (en) | Compounds and their use | |
GB0316204D0 (en) | Compounds and their use | |
GB0316203D0 (en) | Compounds and their use | |
GB0316114D0 (en) | Compounds and their use | |
GB0316112D0 (en) | Compounds and their use | |
GB0316090D0 (en) | Compounds and their use | |
GB0314295D0 (en) | Compounds and their use | |
GB0314293D0 (en) | Compounds and their use |